P-25 – Prof. Dr. Andras Szasz - Oncothemia Consensus

Oncothemia Consensus
Prof. Dr. Andras Szasz
CSO of Oncotherm Group, Tinsdorf, Germany, Szasz@oncotherm.de

Objective
Oncothemia became a widely used and popular method in over 15 countries of the world. It is not a "gold standard" yet, but it is one of the most effective and important methods among the new generation of oncotherapy modalities. It has wide scope applicability for every solid tumor in all possible localizations, irrespective of primary or metastatic form. It could be applied together with all known oncotherapy methods and is applicable in higher lines of the therapy protocols, even in the neoadjuvant and adjuvant cases as well. Its applicability contains the dynamic and absolute approach as well as it is well preserved to provide the optimal available treatment for the given case. Our objective is to propose a consensus for various treatment conditions, to make a frame of the protocols which can be filled up by the actual and well personalized details.

Method
A comprehensive book [37] and numerous scientific and technical papers were published on oncothemia, so the technical basis is stable. Oncothemia has existed during its 21-year existence a massive expertise and large data collection, which are the basis of any convention for treatment protocols. The main factors to its personalized protocol are (1) kind of the complementary treatment; (2) location basis is the protocol of the "gold standard" therapy; (3) kind of the tumor entity; (4) kind of the personal status (5) physiologic factors of the patient. The most frequently applied oncotherapy treatments are the oncotherm combinations with chemotherapy or radiotherapy.

Patient is a part of a resonant circuit

Easy to use, convenient to try

Oncothemia works on conduction principles: RF current flows through the patient from one electrode to the other one. Electrodes are flat plates, both under water pillow, one is under the balloon and the other under the water matress. Water is a transmitter of the RF current, making a possible a good fill of the human body to the flat metal. Both water electrodes (the water bed and the water balloon) are parts of the highly sophisticated electric circuit and not only a matter of convenience. The well conducted device does not radiate, the RF energy flows in a controlled way to the cancerous tissue, the current delivers the energy, where the malignancy is. Both electrodes are active, current flows through them in all frequency periods.

Oncothemia is a personalized, systemic treatment. Oncothemia, in most of the cases, is applied when the conventional cancer therapy fails, when the treatments have reached their limitations or when the patient is not a candidate for conventional treatments. Oncothemia is focused on patient centered values: survival, quality of life and quality of life. Oncothemia can be applied as single or multiple modality (radio, chemo, oncotherapy and additions to surgery (adjacent or neo-adjuvant) as well as some supportive therapy (vitamins, enzymes, etc.) can be given alongside. Oncothemia is a systemic treatment for various solid tumors. Its applicability is not limited to specified applicators. Its universal applicability could be easily fitted to all the "gold standards" as well as it could be a good complementary support for other oncotherapies.

Results
Oncothemia consensus for TREATMENT
1. Apply only in combination (exception if the conventional treatments are not applicable)
2. Treatment time is 45-60 min (average 60 min)
3. Treatment frequency 2-3 times a week (sometimes daily low-dose for blood perfusion)
4. Treatment number 4-123 cycles (average 5.5)
5. Treatment cycle follows the combination (average 3.3)
6. Treatment cycle follows the combination (average 3.3)
7. Treatment cycle follows the combination (average 3.3)
8. Treatment cycle follows the combination (average 3.3)
9. Treatment cycle follows the combination (average 3.3)
10. Treatment cycle follows the combination (average 3.3)

Conclusions
Oncothemia is a systemic therapy for various solid tumors. Its applicability is not limited to specified applicators. Its universal applicability could be easily fitted to all the "gold standards" as well as it could be a good complementary support for other oncotherapies.

References